Download Library

Download Library

Document Type
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial
Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX
Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase II Study
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase II Study
Q3 2017 Results Podcast
Q3 2017 Results Podcast
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH poster - December 2017 (Spencer)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH poster - December 2017 (Spencer)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH poster - December 2017 (Yimer)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH poster - December 2017 (Yimer)
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH presentation - December 2017 (Chari)
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH presentation - December 2017 (Chari)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH poster - December 2017 (Lentzsch)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH poster - December 2017 (Lentzsch)
Citi 2017 Global Healthcare Conference - December 2017
Citi 2017 Global Healthcare Conference - December 2017
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH poster - December 2017 (Chari)
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH poster - December 2017 (Chari)
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH poster - Decem
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH poster - Decem
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH poster - December
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH poster - December
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH poster - December
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH poster - December
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH presentation - December 2017 (Dimopoulos)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH presentation - December 2017 (Dimopoulos)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH poster - December 2017 (Plesner)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH poster - December 2017 (Plesner)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH poster - December 2017 (van de Donk)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH poster - December 2017 (van de Donk)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH poster - December 2017 (Facon)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH poster - December 2017 (Facon)
Daratumumab Monotherapy For Patients With Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase 2 Study - ASH presentation - December 2017 (Hofmeister)
Daratumumab Monotherapy For Patients With Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase 2 Study - ASH presentation - December 2017 (Hofmeister)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH poster - December 2017 (More
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH poster - December 2017 (More
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH poster - December 2017 (Usmani)
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH poster - December 2017 (Usmani)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MM1001) - ASH poster - December 2017 (Lonial)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MM1001) - ASH poster - December 2017 (Lonial)